G Medical Innovations Holdings Ltd

G Medical Innovations Holdings Ltd. engages in the development of mobile and e-health solutions and monitoring service platforms. It operates through the following segments: Products, Patient Services, and Covid-19 Testing. The Products segment includes the development, manufacture, and marketing of trans-telephonic and wireless diagnostic equipment for the medical industry and consumer market. The Petient Services segment comprises cardiac monitoring services of MCT, Patch, Event, Extended Holter, and Pacemaker. The Covid -19 Testing segment covers three kinds of diagnostic tests which are Rapid Antigen + A/B Flu Combo test, PCR test, and Antibody test. The company was founded in August 2014 and is headquartered in George Town, Cayman Islands.

G Medical Innovations Holdings Ltd. operates as a mobile health and digital health company, which engages in the development and marketing clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for remote monitoring and telemedicine projects. It operates through the following segments: Products, Patient Services, and Covid-19 Testing, and Kits. The Products segment includes the development, manufacture, and marketing of trans-telephonic and wireless diagnostic equipment for the medical industry and consumer market. The Patient Services segment focuses on cardiac monitoring services of MCT, Patch, Event, Extended Holter, and Pacemaker. The Covid -19 Testing segment covers three kinds of diagnostic tests which are Rapid Antigen + A/B Flu Combo test, PCR test, and Antibody test. The Kits segment engages in direct-To-Customer health testing kits health issues ranging from food sensitivity, indoor/outdoor allergies, HPV, thyroid functioning, testosterone levels, and the hemoglobin A1C test. The company was founded in August 2014 and is headquartered in George Town, Cayman Islands.

REHOVOT, Israel , May 20, 2024 /PRNewswire/ -- G Medical Innovations Holdings Ltd. (GMVD), a telehealth, medical device, and remote patient monitoring company, announced today a Partnership with Peter N Nielsen to Drive Health and Wellness Innovation.

G Medical Innovations Holdings Ltd. Announces a Partnership with Peter N Nielsen to Drive Health and Wellness Innovation

G Medical Innovations (NASDAQ: GMVD ) stock is climbing higher on Tuesday without any clear news from the healthcare company. G Medical Innovations hasn't put out any new press releases that explain why GMVD stock is up today.

Why IS G Medical Innovations (GMVD) Stock Up 34% Today?

Rehovot, Israel, Aug. 17, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical Innovations”), an industry innovator in comprehensive remote patient monitoring solutions, today announced that its wholly-owned subsidiary, G Medical Innovations USA, Inc., has entered into an agreement with Resilient Support Services Inc. (“RSS”) to expand the health care and remote patient monitoring capabilities to U.S. veterans and military personnel. RSS is a Service-Disabled Veteran-Owned Business that partners with U.S. federal agencies and private sector businesses that are concerned with improving the medical care of veterans and the military community.

G Medical Innovations Will Provide Services to Veterans and Military Personnel by Partnering With Resilient Support Services

G Medical Innovations (NASDAQ: GMVD ) stock is on the rise Tuesday despite a lack of news concerning the mobile health and telemedicine solutions company. There are no new press releases, or filings with the Securities and Exchange Commission (SEC), that explain today's stock movement.

Why Is G Medical Innovations (GMVD) Stock Up 32% Today?

Rehovot, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical Innovations” or the “Company”), a global leader in next-generation mobile health (mHealth) and digital health, today issued the following update to shareholders from President and CEO Dr. Yacov Geva.

G Medical Innovations' CEO Issues Update to Shareholders, August 2023

Allarity Therapeutics

BIOLASE

Penumbra

ZyVersa Therapeutics Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off In August

Inpixon

Moatable Inc

The9 Ltd. Sponsored

Soluna Holdings, Inc.

T2 Biosystems

Gaucho Group Holdings

Much like baseball, the investing game yields success through mitigated failure, which brings us to the topic of doomed stocks to avoid. No matter who you are, you will never achieve a perfect lifetime record in the capital market.

7 Doomed Stocks Destined for Disaster

Rehovot, Israel, May 19, 2023 (GLOBE NEWSWIRE) --  G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”), a telehealth, medical device, and remote patient monitoring company, announced today that on May 15, 2023 it received a written notice (the “Notice”) from Nasdaq Stock Market LLC, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, the Company's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “GMVD”, subject to the Company meeting the conditions set forth by the Nasdaq Hearings Panel (the “Panel”) related to Nasdaq's shareholders equity requirement pursuant to the letter received from the Panel on May 11, 2023 as described by the Company on its press release dated May 15, 2023.

G Medical Innovations Holdings Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

Rehovot, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”) announced today that, on May 11, 2023, the Company received notice from the Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) that the Panel has granted the request of the Company to continue its listing on Nasdaq, subject to the conditions described below.

G Medical Innovations Holdings Ltd. Announces Receipt of Nasdaq Hearings Panel's Decision to Grant Exception for Continued Listing

BGC Partners

Baudax Bio

Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 3 To Watch Today

Rehovot, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical"), a global leader in next-generation mobile health (mHealth) and digital health, is excited to report that patient enrollment has grown in its home monitoring services by 194% between January and April of 2023, as compared to the same period last year. The increase is due to growing demand for homecare monitoring. As previously announced, in the first quarter of 2023, G Medical signed an agreement with AdventHealth of Central Florida (“AdventHealth”), an operator of 20 hospitals and emergency rooms. AdventHealth experiences on average 5.7 million patient visits per year. G Medical also recently signed an agreement with MiCare Path to integrate MiCare Path's software platform and visualization tools to its devices. By integrating MiCare Path's virtual health solutions with G Medical's global health solutions and devices, physicians and patients will benefit from the next-generation care driving better outcomes for patients across all services. The G Medical collaboration will allow for a total remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) solution from service to exceptional future solutions. The Company looks forward to announcing additional key agreements in 2023.

G MEDICAL UPDATES ON PATIENT ENROLLMENT GROWTH FOR ITS HOME MONITORING SERVICES OF 194% FROM JANUARY THROUGH APRIL 2023, AS COMPARED TO THE SAME PERIOD IN 2022

Rehovot, Israel, April 04, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”), a global leader in next-generation mobile health (mHealth) and digital health, today announced the closing of its public offering of 12,000,000 ordinary shares (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof), each sold to the public at a price of $0.80 (inclusive of the exercise price of the Pre-Funded Warrant) for gross proceeds of approximately $9.6 million, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,800,000 ordinary shares and/or Pre-Funded Warrants to cover over-allotments at the public offering price, less the underwriting discount.

G Medical Innovations Holdings Ltd. Announces Closing of Public Offering

Rehovot, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”), a global leader in next-generation mobile health (mHealth) and digital health, today announced the pricing of an underwritten public offering of 12,000,000 ordinary shares (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof). Each ordinary share (or Pre-Funded Warrant) is being sold to the public at a price of $0.80 (inclusive of the exercise price of the Pre-Funded Warrant) for gross proceeds of approximately $9.6 million, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,800,000 shares and/or Pre-Funded Warrants to cover over-allotments at the public offering price, less the underwriting discount.

G Medical Innovations Holdings Ltd. Announces Pricing of Public Offering

Rehovot, Israel, March 27, 2023 (GLOBE NEWSWIRE) --  G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical Innovations”), a global leader in next-generation mobile health (mHealth) and digital health, and MiCare Path, a leader in optimized patient care through remote patient monitoring, today announced a collaboration to incorporate MiCare Path's solutions and G Medical Innovations' solutions. As part of the collaboration, G Medical Innovations' hardware devices will be integrated with MiCare's software platform and visualization tools to provide remote patient monitoring services. The partnership brings together two innovative companies with a shared vision of transforming the healthcare industry by leveraging technology and providing patient-centered care. MiCare Path brings its large hospital system presence and optimized patient care platform to drive digital science to deliver the future of healthcare.  G Medical Innovations was a chosen partner for MiCare Path due to its innovative and scalable solution for building and fostering health technology.

G MEDICAL INNOVATIONS AND MICARE PATH ANNOUNCE JOINT COLLABORATION TO PROVIDE INNOVATIVE REMOTE PATIENT MONITORING SOLUTIONS GLOBALLY

Rehovot, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”) announced today that on February 16, 2023, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company's non-compliance with the stockholders' equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b) (the “Equity Rule”), the Company is subject to delisting from Nasdaq unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”).  Accordingly, the Company plans to timely request a hearing before the Panel, which will stay any delisting or suspension action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing.

G Medical Innovations Holdings Ltd Announces Nasdaq Staff Listing Determination; Plans to Request Hearing

Rehovot, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical Innovations”) today announced that the patent US 11,571,167 “Method and System For Vital Signs Monitoring With Earpiece” has been issued as of February 7, 2023.

G Medical Innovations announces receipt of patent from USPTO for vital signs sensors

Aethlon Medical

Heart Test Laboratories Inc

Can these technical indicators help you make money with penny stocks? The post 3 Tips for Using Technical Indicators to Find Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Tips for Using Technical Indicators to Find Penny Stocks to Buy

G Medical Innovations (NASDAQ: GMVD ) stock is on the rise Monday following an update from the U.S. Patent and Trademark Office (USPTO). This has G Medical Innovations receiving a patent issue notification from the USPTO.

Why Is G Medical Innovations (GMVD) Stock Up 94% Today?

Rehovot, Israel, Jan. 30, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical Innovations”) today announced that it has received a patent issue notification from the United States Patent and Trademark Office (“USPTO”) for its monitoring products marketed in the United States. The patent, expected to be issued on February 7, 2023, Method and System for Vital Signs Monitoring with Earpiece, covers the vital signs monitoring system that the Company is developing using multiple sensing mechanisms to be used on different body locations. This vital sign monitoring system will potentially provide physicians more versatility in patients' monitoring and would simplify in and out-patients' monitoring.

G Medical Innovations announces receiving notice of patent issuance from the USPTO for vital signs sensors

NEW YORK , Dec. 7, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against G Medical Holdings Ltd ("G Medical" or the "Company") (NASDAQ: GMVD). Investors who purchased G Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/gmvd.

Bronstein, Gewirtz & Grossman, LLC Announces G Medical Holdings Ltd (GMVD) Investigation

Irvine, California, Dec. 05, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the “Company” or “G Medical Innovations”) today announced that it received 2 (Two) granted patents from the United States Patent and Trademark office for its monitoring products marketed in the U.S. market.

G Medical Innovations to announce receiving of 2 (two) granted patents from the USPTO for its Prizma care and other physiological sensors developed by the company.

New York, New York--(Newsfile Corp. - November 30, 2022) - Pomerantz LLP is investigating claims on behalf of investors of G Medical Holdings Ltd ("G Medical" or the "Company") (NASDAQ: GMVD). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether G Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of G Medical Holdings Ltd - GMVD

Irvine, California, Nov. 22, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, has received today a written notice (the “Notice”) from Nasdaq Stock Market LLC, indicating that the Company is no longer in compliance with the minimum shareholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Rule 5550(b)(1) requires listed companies to maintain shareholders' equity of at least $2,500,000. Further, the Company did not meet the alternative compliance standards relating to the market value of listed securities or net income from continuing operations, as set forth in Nasdaq Rule 5550(b)(1). In accordance with Nasdaq Rule 5810(c)(2)(A), the Company has 45 calendar days, or until January 6, 2023, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance. The Notice has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares on the Nasdaq Capital Market under the symbol “GMVD”.

G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (“G Medical” or the “Company”), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022.

G Medical Innovations Announces First Half 2022 Financial Results and Provides Business Update

G Medical Innovations is introducing a Monkeypox consumer home health test kit, along with 30 new direct to consumer home health testing kits with 24 to 48 hours results

News for G Medical Innovations Holdings Ltd Stock (GMVD)